BRISBANE, Australia--(BUSINESS WIRE)--Australian drug developer, Alchemia Limited (ASX:ACL), today announced agreement on the HA-irinotecan clinical development program, following a pre-investigational new drug (pre-IND) meeting with the United States (US) Food & Drug Administration (FDA).
